Adjuvant endocrine therapies for pre-/perimenopausal women

Breast

Volumn 14, Issue 6, 2005, Pages 547-554

  Pritchard, Kathleen I ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Adjuvant therapy; Breast cancer; Perimenopausal; Postmenopausal; Predictive factors; Premenopausal

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; MELPHALAN; METHOTREXATE; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; RALOXIFENE; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLIMACTERIUM; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFICACY; FEMALE; GYNECOLOGIC SURGERY; HUMAN; META ANALYSIS; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; SYSTEMIC THERAPY;

EID: 27244438641     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.09.002     Document Type: Article

References (54)

1. G.T. Beatson On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases Lancet 2 1896 104-107
2. A. Schinzinger Über carcinoma mammae Verh Dtsch Ges Chir 18 1889 28-29
3. Early Breast Cancer Trialists' Collaborative Group Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women N Engl J Med 319 1988 1681-1692
4. Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Lancet 339 1-15A 1992 71-85
5. K.I. Pritchard editor. Ovarian ablation as adjuvant therapy for premenopausal women with early breast cancer: Phoenix arisen? (Editorial) Lancet 339 1992 95-96
6. Oxford Overview, 2000. www.ctsu.ox.ac.uk.
7. C.W. Taylor S. Green W.S. Dalton S. Martino D.J. Rector J.N. Ingle et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study J Clin Oncol 16 1998 994-999
8. F. Boccardo R. Blamey J.C.M. Klijn T. Tominaga L. Duchateau R. Sylvester LHRH-Agonist (LHRH-A)+tamoxifen (TAM) versus LHRH-A alone in premenopausal women with advanced breast cancer (ABC): Results of a meta-analysis of four trials Proc Am Soc Clin Oncol 18 1999 110a
9. J.G. Klijn R.W. Blamey F. Boccardo T. Tominaga L. Duchateau R. Sylvester Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials J Clin Oncol 15 2001 343-353
10. N. Davidson A. O'Neill A. Vukov C.K. Osborne S. Martino D. White et al. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101) Proc Am Soc Clin Oncol 18 1999 67a
11. L.E. Rutqvist Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomized trial by the Cancer Research Campaign (C.R.C.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Group & the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G.I.V.I.O.) Proc Am Soc Clin Oncol 18 1999 67a
12. Scottish Cancer Trials Breast Group Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial Lancet 341 1993 1293-1298
13. E. Engelsman J.C.M. Klijn R.D. Rubens et al. Classical CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer Eur J Cancer 27 1991 966-970
14. B. Ejlertsen P. Dombernowski H.T. Mouridsen C. Kamby M. Kjaer C. Rose et al. Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP) Proc Am Soc Clin Oncol 18 1999 66a
15. R. Jakesz H. Hausmaninger E. Kubista M. Gnant C. Menzel T. Bauernhofer et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial J Clin Oncol 20 2002 4621-4627
16. W. Jonat M. Kaufmann W. Sauerbrei R. Blamey J. Cuzick M. Namer et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study J Clin Oncol 20 2002 4628-4635
17. G. Von Minckwitz E. Graf M. Geberth W. Eiermann W. Jonat B. Conrads et al. Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 Trial ASCO Proc 23 2004 10
18. D. Wallwiener K. Possinger P. Schmid V. Tarutinov L. Suchina H. Hillger et al. A Phase III trial comparing adjuvant treatment with leuprorelin acetate 3M-Depot for 24 months with CMF chemotherapy in ER/ PR+node+pre-perimenopausal breast cancer patients ASCO Proc 23 2004 10
19. M.N. Levine V.H. Bramwell K.I. Pritchard B.D. Norris L. Shepherd H. Abu-Zahra et al. A randomized trial of cyclophosphamide, epirubicin, fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, fluorouracil in premenopausal women with node positive breast cancer J Clin Oncol 16 1998 2651-2658
20. I.C. Henderson D. Berry G. Demetri C. Cirrincione L. Goldstein S. Martino et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer. For CALGB, ECOG, SWOG, and NCCTG Proc Am Soc Clin Oncol 17 1998 390a
21. K.I. Pritchard Adjuvant therapy for premenopausal women with breast cancer: Is it time for another paradigm shift? J Clin Oncol 20 2002 4611-4614
22. H.W.C. Ward Antiestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels Br Med J 1 1973 13-14
23. K.I. Pritchard D.B. Thomson R.E. Myers D.J.A. Sutherland B.G. Mobbs J.W. Meakin Tamoxifen therapy in premenopausal patients with metastatic breast cancer Cancer Treat Rep 64 1980 787-796
24. G.G. Ribeiro R. Swindell The Christie Hospital adjuvant tamoxifen trial - status at 10 years Br J Cancer 57 1988 601-603
25. Scottish Cancer Trials Breast Group Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial Lancet 2 1987 171-175
26. C. Rose K.W. Andersen H.T. Mouridsen Beneficial effect of adjuvant tamoxifen in primary breast cancer patients with high oestrogen receptor values Lancet 1 1985 16-19
27. K.I. Pritchard J.W. Meakin N.F. Boyd A.H.G. Paterson U. Ambus G. DeBoer et al. A randomized trial of adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer 1990 Oxford Medical Publishers Oxford
28. Nolvadex Adjuvant Trial Organization Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer. Analysis at eight years by the Nolvadex Adjuvant Trial Organization Br J Cancer 57 1988 608-611
29. B. Fisher J. Costantino C. Redmond R. Poisson D. Bowman J. Couture et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors N Engl J Med 320 1989 479-484
30. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: An overview of the randomized trials Lancet 351 1998 1451-1467
31. V.H. Bramwell K.I. Pritchard Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: Is it standard practice or still a subject for study? Eur J Cancer 35 1999 1625-1627
32. M. Andersson Danish Breast Cancer Cooperative Group Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy Eur J Cancer 35 1999 1659-1666
33. L. Hutchins S. Green P. Ravdin D. Lew S. Martino M. Abeloff et al. CMF versus CAF±tamoxifen in high-risk node-negative breast cancer patients and a natural history of follow-up study in low-risk node negative patients: Update of tamoxifen results Breast Cancer Res Treat 57 1999 25
34. C.K. Osborne Effects of estrogen and antiestrogens on cell proliferation. Implications for treatment of breast cancer In: C.K. Osborne editor. Endocrine treatment in breast and prostate cancer 1988 Kluwer Boston 11-129
35. G.J. Goldenberg E.K. Froese Antagonism of the cytocidal activity and uptake of an melphalan by tamoxifen in human breast cancer cells in vitro Biochem Pharmacol 34 1985 763-770
36. K. Albain S.J. Green P.M. Ravdin C. Cobau E. Levine J. Ingle et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG-8814) Proc Am Soc Clin Oncol 21 2002 37a
37. M. Colleoni International Breast Cancer Study group (IBCSG) BS Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with node-positive (N+), early stage breast cancer: First results of International Breast Cancer Study Group Trial 13-93 ASCO Proc 23 2004 10
38. R. Paridaens J. Dyczka E. Rutgers R. Coleman T. Cufer J. Jassem et al. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer. First results of a randomized phase III trial EORTC 10901 EJC supplements 4th European breast cancer conference 2 2004 70
39. M. Citron D.A. Berry C. Cirrincione C. Hudis E.P. Winer W.J. Gradishar et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and leukemia group B trial 9741 J Clin Oncol 21 2003 1431-1439
40. M.J. Ellis A. Coop B. Singh L. Mauriac A. Llombert-Cussac F. Jänicke et al. Letrozole is more effective neoadjuvant therapy than tamoxifen for ErbB1 and ErbB2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial J Clin Oncol 19 2001 3808-3816
41. B.A. Gusterson R.D. Gelber A. Goldhirsch et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group J Clin Oncol 7 1992 1049-1056
42. D.C. Allred G.M. Clark A.K. Tandon et al. Her-2/neu in node negative breast cancer: Prognostic significance of over-expression influenced by the presence of in situ carcinoma J Clin Oncol 10 1992 599-605
43. A.D. Thor D.A. Berry D.R. Budman H.B. Muss T. Kute I.C. Henderson et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer J Natl Cancer Inst 90 1998 1346-1360
44. S. Paik J. Bryant E. Tan-Chiu G. Yothers C. Park D.L. Wickerham HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 J Natl Cancer Inst 92 2000 1991-1998
45. S. Paik J. Bryant C. Park B. Fisher E. Tan-Chiu D. Hayms et al. erbB-2 and response to doxorubicin in patients with axillary lymph node positive, hormone receptor negative breast cancer J Natl Cancer Inst 90 1998 1361-1370
46. A. Di Leo D. Larsimont M. Beauduim CMF or anthracycline-based adjuvant chemotherapy for node-positive breast cancer patients: 4 year results of a Belgian randomized clinical trial with predictive markers analysis Proc Am Soc Clin Oncol 18 1999
47. A. Di Leo D. Larsimont M. Beauduim Her-2 and topoisomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide Ann Oncol 12 2001 1081-1089
48. P.C. Clahsen C.J.H. van de Velde C. Duval C. Pallud A.M. Mandard A. Delobelle-Deroide p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer J Clin Oncol 16 1998 470-479
49. P.M. Ravdin S. Green K. Albain J. Boucher J. Ingle K.I. Pritchard et al. Initial report of the SWOG biological correlative study of C-ERBB-2 expression as a prediction of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone Proc Am Soc Clin Oncol 17 1998 97a
50. K. Albain S. Green K. Osborne C. Cobau E. Levine J. Ingle et al. Tamoxifen (T) versus cyclophosphamide, adriamycin and 5-FU plus either concurrent or sequential T in postmenopausal receptor (+), or node (+) breast cancer: A Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100) Proc Am Soc Clin Oncol 16 1997 128a
51. A. Lipton S. Ali K. Leitzel V.M. Chinchilli L. Engle L. Demers et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer Proc Am Soc Clin Oncol 19 2000 274
52. R.R. Love N.B. Duc T. Havighurst S.K. Mohsin Q. Zhang D.L. DeMets et al. HER2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer J Clin Oncol 21 2003 453-457
53. F. Boccardo A. Rubagotti D. Amoroso M. Mesiti D. Romeo P. Sismondi et al. Cyclosphosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial J Clin Oncol 18 2000 2718-2727
54. H. Roche P. Kerbrat J. Bonneterre P. Fargeot P. Fumoleau A. Monnier et al. Complete hormonal, blockade versus chemotherapy in premenopausal early stage breast cancer patients with positive hormone-receptor and 1-3 node-positive tumor: Results of the FASG 06 trial Proc Am Soc Clin Oncol 19 abstr. 279 2000